Shire
Clinical trials sponsored by Shire, explained in plain language.
-
New hope for rare brain disease: Long-Term safety data collected
Disease control CompletedThis study followed 24 people with metachromatic leukodystrophy (MLD), a rare and serious brain disease, who were already receiving an experimental drug called HGT-1110. The main goal was to check for side effects and immune reactions over a long period. Researchers wanted to see…
Phase: PHASE1, PHASE2 • Sponsor: Shire • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Early enzyme therapy may help kids with rare disease grow better
Disease control CompletedThis study followed 21 boys with Hunter syndrome who started taking Elaprase before age 6. Researchers tracked their height and weight for at least 5 years to see if the drug helps them grow more like other children. The study also monitored safety and compared growth data to unt…
Phase: PHASE4 • Sponsor: Shire • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Real-World data shows lanadelumab cuts HAE attacks over three years
Disease control CompletedThis study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab. Researchers compared the number of swelling attacks during treatment to the number before starting the drug. Participants reported their symptoms via a smartphone app and during c…
Sponsor: Shire • Aim: Disease control
Last updated Jun 26, 2026 13:06 UTC
-
New hope for kids with ADHD who Don't respond to stimulants
Symptom relief CompletedThis study looked at whether a long-acting medication called guanfacine (TAK-503) can help children and teenagers aged 6 to 17 with ADHD who did not get better with standard stimulant treatments. The study had two parts: first, participants were randomly assigned to receive guanf…
Phase: PHASE4 • Sponsor: Shire • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Do patients and doctors really understand this parathyroid drug?
Knowledge-focused CompletedThis study checked how well patients and doctors understand the risks and safe use of NATPARA, a drug for hypoparathyroidism. About 200 people took a survey online, by phone, or on paper. No medicine was given—the goal was just to measure knowledge and attitudes.
Sponsor: Shire • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Maribavir drug study compares japanese and caucasian adults
Knowledge-focused CompletedThis early-stage study tested a single dose of the drug maribavir in 24 healthy adults—12 of Japanese descent and 12 of non-Hispanic Caucasian descent. The goal was to see if the drug behaves differently in these groups and to check safety. Participants took different doses to un…
Phase: PHASE1 • Sponsor: Shire • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:07 UTC